Skip to main content

Table 4 Medication exposure from the time of drug initiation to the end of study period

From: BK viruria and viremia in children with systemic lupus erythematosus

Type of biologic exposure No. of patients
[N = 32 (%)]
Overall
cumulative dose (grams) [median, range]
Cumulative dose/body weight (mg/kg) [median, range] # of doses [median, range] Length of exposure since diagnosis in days
[median, range]
Abatacept 4 (12.5) 15.3 (3.6–26.2) 231.6 (108–375) 21 (8–28) 540.5 (169–732)
Adalimumab 1 (3.1) 480 10.2 12 159
Belimumab 3 (9.3) 3.9 (1–5.3) 75.5 (18.7–78.1) 8 (2–8) 176 (16–235)
Infliximab 2 (6.25) 4.7 91.8 11.5 299
Rituximab 29 (90.6) 5.0 (1.8–9.9) 89.1 (18–192.1) 8 (2–12) 503 (96-12,226)
Tocilizumab 2 (6.25) 3.4 57.9 8 196.5
Ivig (g/kg) 12 (37.5) 263.5 (1–14,193) 6.85 (1–39.8) 11.5 (1–47) 241.5 (1-1462)
Ever received Non-biologics No. Of patients [N = 32 (%)] Overall cumulative dose (grams) [median, range] Cumulative dose/body weight (mg/kg) [median, range] # of doses [median, range] Length of exposure since diagnosis in days
[median, range]
Azathioprine 2 37.7 790.6 N/A 496
Cyclophosphamide 15 (46.8) 7.1 (4.3–12.7) 94.6 (40.3–295) 6 148 (84-1152)
Hydroxy-chloroquine 25 (78.1) N/A N/A N/A 536 (72–2801)
Methotrexate 4 (12.5) 1.2 (0.5–2.3) 20.3 (11.9–42.7) N/A 354 (224–1167)
Mycophenolate 28 (87.5) 1109 (128–6751) 23,680
(1950–400,720)
N/A 921.5
(38-2261)
Prednisone 30 (93.7) 6.1 (0.1–25.4) 95.35 (2.3–542.4) N/A 525.5 (5-3987)
Solu-medrol 32 (100) 10.4 (3–60) 158.9 (41–1272) 16 (3–60) 547.5 (1-1788)
  1. N/A not applicable